bio-clinical-biostatistics-adaptive-designs

What this skill does

## Version Compatibility

Reference examples tested with: R `rpact` 4.2+ (Wassmer/Brannath), `gsDesign` 3.6+ and `gsDesign2` 1.1+ (Anderson/Merck), `adaptr`, `simtrial`. Commercial: East/EastHorizon (Cytel), ADDPLAN (ICON), FACTS (Berry Consultants).

Before using code patterns, verify installed versions match. If versions differ:
- R: `packageVersion('<pkg>')` then `?function_name`
- Python adaptive packages are limited; R is the regulatory de facto standard

If code throws an error, introspect the installed package and adapt the example to match the actual API rather than retrying.

# Adaptive Clinical Trial Designs

**"Design an adaptive trial"** -> Pre-specify a design with one or more interim adaptations (early stopping, sample-size re-estimation, treatment selection, population enrichment, randomisation ratio changes) that strongly controls Type-I error at the trial-wide level via combination tests or the Conditional Rejection Probability principle.

## Regulatory Status -- The 2024-2026 Landscape

**FDA 2019 Final Adaptive Designs Guidance** (Federal Register 2019-25986, Dec 2 2019) finalised the 2010 and 2018 drafts. Recognises 5 design types: group-sequential, blinded SSR, unblinded SSR, adaptive enrichment, adaptive randomisation.

**FDA 2022 Final Master Protocols Guidance** (March 2022, NOT 2018 — common citation error): basket (one drug, many diseases), umbrella (multiple drugs, one disease), platform (perpetual, drugs enter/exit).

**ICH E20 Adaptive Clinical Trials**: **Step 2b draft June 25 2025; Step 3 public consultation (EU deadline Nov 30 2025; FDA Federal Register Sept 30 2025); Step 4 final targeted late 2026.** As of May 2026, ICH E20 is NOT final. The EFPIA/PhRMA position paper preceded the formal ICH work; Berry Consultants public comment letter is one of the more important submissions.

**FDA CDER Bayesian Methodology Draft (Jan 2026)** (FDA-2025-D-3217): first-ever drug-side Bayesian guidance; permits Bayesian primary inference in pivotals with simulation-based Type-I error calibration.

**Project Optimus (FDA OCE, 2021-2024)**: rewrites Phase I/II oncology by requiring randomised dose comparison before registration, replacing MTD-and-go. Made BOIN, mTPI-2, and multi-arm dose-finding the default.

## Algorithmic Taxonomy

| Design type | Adaptation | Type-I preservation | Software | Strength | Fails when |
|-------------|-----------|---------------------|----------|----------|------------|
| Group-sequential (O'Brien-Fleming) | Early stopping for efficacy/futility | Boundary calculation; very conservative early, near-nominal at end | rpact, gsDesign | FDA's preferred adaptive design | More complex SAP; IDMC firewall essential |
| Group-sequential (Pocock) | Early stopping | Constant nominal alpha at each look | rpact, gsDesign | Easy early stopping | Large penalty at final analysis |
| Wang-Tsiatis power family | Early stopping | Parameterised by Delta | rpact | Tunable conservatism | Δ choice matters |
| Lan-DeMets spending function | Early stopping (flexible timing) | Alpha-spending function | rpact, gsDesign | Operational flexibility; analyses don't need pre-specified number | FDA's de facto preferred framework |
| Blinded SSR (Friede-Kieser 2006) | Re-estimate variance/event-rate; recompute n | No Type-I inflation; agency-uncontroversial | rpact | EMA/FDA endorsed | Variance estimate must be blinded |
| Unblinded SSR (Cui-Hung-Wang 1999) | Increase n based on interim effect estimate | Requires CHW weights for control; or Mehta-Pocock promising zone | rpact | Recovers power if interim promising | IDMC firewall must be perfect; Jennison-Turnbull 2015 critique |
| Mehta-Pocock promising zone (2011) | Increase n if conditional power in (0.3, 0.8) | Calibrated so Type-I inflation negligible (~0.001) | rpact | Operational simplicity | "Stealth alpha inflation" critique (Jennison 2015) |
| Bauer-Köhne 1994 combination | Combine stagewise p-values via Fisher product | Any pre-specified design modification | rpact | Most flexible; theoretical foundation | Power loss vs designed group-sequential |
| Müller-Schäfer 2001 CRP principle | Preserve null conditional rejection probability | Any adaptation at any time | rpact | Modern theoretical bedrock | Implementation complexity |
| Adaptive enrichment | Drop sub-populations failing futility | Closed-test stage-wise | rpact, adaptr | Recovers power on responders | Selection bias on enriched population |
| Response-adaptive randomisation | Update allocation probabilities | Stratification + time-trend covariates required | adaptr, FACTS | Patient-welfare; learn-and-confirm | Drift bias, estimator bias; controversial (Hey-Kimmelman 2015 ethics) |
| Bayesian platform (I-SPY 2 style) | RAR + biomarker stratification + graduation criterion | Frequentist OCs via simulation | FACTS, custom Stan/JAGS | Modern oncology adaptive | Operational complexity; requires IDMC sophistication |

**Postdoc reading list:**

- Bauer P, Köhne K 1994 *Biometrics* 50:1029 (combination test; original adaptive)
- Cui L, Hung HMJ, Wang SJ 1999 *Biometrics* 55:853 (CHW weighted test for unblinded SSR)
- Müller HH, Schäfer H 2001 *Biometrics* 57:886 (CRP principle — theoretical bedrock)
- Mehta CR, Pocock SJ 2011 *Stat Med* 30:3267 (promising zone)
- Jennison C, Turnbull BW 2015 *Stat Med* 34(29):3793-3810 (Mehta-Pocock critique)
- Friede T, Kieser M 2006 *Biom J* 48:537 (blinded SSR)
- Lan KKG, DeMets DL 1983 *Biometrika* 70:659 (alpha spending function)
- O'Brien PC, Fleming TR 1979 *Biometrics* 35:549 (OBF boundary)
- Pocock SJ 1977 *Biometrika* 64:191 (Pocock boundary)
- Hey SP, Kimmelman J 2015 *Clin Trials* 12:102 (RAR ethics critique)
- Berry DA 2015 commentary *Clin Trials* 12:107 (counter)
- Robertson DS, Lee KM, López-Kolkovska BC, Villar SS 2023 *Stat Sci* 38:185 (canonical modern RAR review)
- Wassmer G, Brannath W 2016 *Group Sequential and Confirmatory Adaptive Designs in Clinical Trials* (Springer)
- Jennison C, Turnbull BW 2000 *Group Sequential Methods with Applications to Clinical Trials* (CRC)

## Decision Tree by Scenario

| Scenario | Recommended approach | Why |
|----------|---------------------|-----|
| Confirmatory trial wanting interim early stopping | Group-sequential with O'Brien-Fleming boundaries via gsDesign | FDA-preferred; near-nominal final alpha |
| Group-sequential with flexible look timing | Lan-DeMets spending function | Operational flexibility; FDA de facto preferred |
| Phase 3 with uncertain nuisance parameter (variance, event rate) | Blinded SSR (Friede-Kieser) | No Type-I inflation; agency-uncontroversial |
| Phase 3 wanting to increase n if interim shows promise | Mehta-Pocock promising zone with CHW weights | Recovers power; calibrated Type-I |
| Seamless Phase 2/3 with arm selection | Bauer-Köhne combination test + closed testing | Most flexible; cite Müller-Schäfer CRP |
| Adaptive enrichment (drop subpopulation) | Adaptive enrichment with closed-test stage-wise | Recovers power on responders |
| Multi-arm oncology platform | Bayesian platform with RAR (I-SPY 2 model) | Patient-welfare argument strong for multi-arm |
| 2-arm phase 3 oncology with potential RAR | Avoid RAR; group-sequential preferred | Hey-Kimmelman 2015 ethics + drift bias |
| Continuous endpoint, treatment discontinuation, follow-up data available | Hybrid: J2R imputation for treatment-discontinuation ICEs, MMRM-MAR for other missingness | Aprocitentan PRECISION precedent (2024); FDA de facto standard 2024-2025 for treatment-policy estimands |
| Phase 1 dose-finding | BOIN (FDA Fit-for-Purpose qualified 2021) | Transparent, tabulated decisions; no bedside Bayesian software |
| Phase 1b/2 dose-optimisation (Project Optimus) | Multi-arm BOIN-12 or multi-dose randomised | FDA Aug 2024 final dose-optimisation guidance |
| Basket trial (one drug, multiple diseases) | EXNEX or robust MAP via RBesT | Borrows across baskets while permitting one to detach |
| Umbrella trial (one disease, multiple drugs) | Bay